Andrea S. Blevins Primeau, PhD, MBA

Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.

All articles by Andrea S. Blevins Primeau, PhD, MBA

Patient talking to doctor.

Gastrointestinal Cancers

Changes in Patient-Reported Outcomes Predict Response, Survival in Gastrointestinal Cancers

By

Andrea S. Blevins Primeau, PhD, MBA

October 8, 2021

Treatment response, progression-free survival, and overall survival were all associated with patient-reported outcomes.

Patient undergoing chemotherapy.

Breast Cancer Patients Who Are Not Represented in Clinical Trials Have an Increased Risk of Death

By

Andrea S. Blevins Primeau, PhD, MBA

October 7, 2021

The unrepresented patient population had a significantly increased risk of death at 5 years.

A patient with cancer receives palliative care.

Predicting End of Life for Patients With Metastatic Breast Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

October 6, 2021

Several factors were associated with 30-day mortality.

PSA blood test

PSA Screening Recommendation Tied to Decrease in Prostate Cancer-Specific Survival

By

Andrea S. Blevins Primeau, PhD, MBA

October 5, 2021

The 3-year prostate cancer-specific survival decreased significantly for insured patients.

Doctor and patient

Financial Burden Increasing for Privately Insured Cancer Patients

By

Andrea S. Blevins Primeau, PhD, MBA

September 30, 2021

There was a significant increase in out-of-pocket costs for all 4 cancer types studied.

Masked patient in hospital bed.

Cancer Patients With COVID-19 Less Likely to Receive Critical Care Despite Higher Risk of Death

By

Andrea S. Blevins Primeau, PhD, MBA

September 24, 2021

Cancer patients were less likely to receive critical care, whether they were on active anticancer treatment or not.

Image of rectal cancer.

Neoadjuvant CapeOx May Be Alternative to CRT in Locally Advanced Rectal Cancer

By

Andrea S. Blevins Primeau, PhD, MBA

September 22, 2021

The rate of perioperative distant metastases was significantly lower with CapeOx than with CRT.

Colorectal cancer illustration

TARE Prolongs PFS, Not OS, in Colorectal Cancer With Liver Metastases

By

Andrea S. Blevins Primeau, PhD, MBA

September 21, 2021

The median PFS was 8.0 months with TARE and 7.2 months with chemotherapy alone.

X-ray of human digestive system.

Long-Term Follow-up Confirms Efficacy, Safety of Nivolumab Plus Chemotherapy in Gastrointestinal Cancers

By

Andrea S. Blevins Primeau, PhD, MBA

September 20, 2021

The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow-up.

Doctor talking to patient while taking notes.

Adjuvant Pembrolizumab Prolongs Relapse-Free Survival in Stage II Melanoma

By

Andrea S. Blevins Primeau, PhD, MBA

September 20, 2021

Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.

Next post in ESMO 2021

Sugemalimab Deemed Effective as Consolidation for Stage III Non-Small Cell Lung Cancer